0,1,2,3,4,5,6
,Table 2. Characteristics of invasive mold infections (IMI) and patientsâ€™ outcome.,,,,,
,EORTC,,,Concurrent,Combination,Outcome and
Patient,,Species,Site of IMI,,,
,Classification,,,Infections,Therapy,12-weeks Response
,Possible,,"lung, liver,",coronavirus,L-AMB +,
1,,-,,,,Favourable (CR)
,aspergillosis,,spleen,229E/NL63,caspofungin,
,Probable,,,BSI S.mitis/R.,L-AMB +,
2,,-,lung,,,Favourable (PR)
,aspergillosis,,,mucilaginosa,caspofungin,
,Probable,,,,L-AMB +,"Failure, death due to"
3,,-,"lung, CNS",RSV B,,
,aspergillosis,,,,voriconazole,IMI
,Proven IMI,,,,,
,,,"lung, liver,",,L-AMB +,
4,(probable,-,,No,,Favourable (CR)
,,,spleen,,caspofungin,
,aspergillosis),,,,,
,Probable,,,BSI S.,L-AMB +,
5,,-,"lung, CNS, liver",,,Favourable (PR)
,aspergillosis,,,Epidermidis,voriconazole,
,Proven,Absidia,,,L-AMB +,
6,,,rinocerebral,No,,Favourable (CR)
,mucormycosis,corymbifera,,,posaconazole,
,Proven,Untyped,rhino-orbito-,,L-AMB +,
7,,,,No,,Favourable (CR)
,mucormycosis,mucorales,cerebral,,posaconazole,
,Proven,Fusarium,,rinovirus,L-AMB +,
8,,,"BSI, skin",,,Favourable (CR)
,fusariosis,subglutinans,,A/B/C,voriconazole,
,Possible,,,,L-AMB +,"Failure, death due to"
9,,-,lung,No,,
,aspergillosis,,,,posaconazole,HD
,Probable,,,,L-AMB +,"Failure, death due to"
10,,-,"lung, CNS",CMV viremia,,
,aspergillosis,,,,voriconazole,IMI
,Probable,,,BSI P.,L-AMB +,
11,,-,lung,,,Favourable (PR)
,aspergillosis,,,aeruginosa,caspofungin,
,Possible,,,VZV Zoster,L-AMB +,
12,,-,lung,,,Favourable (CR)
,aspergillosis,,,C5-C7,voriconazole,
,Proven,Aspergillus,"lung,",K.pneumoniae,L-AMB +,"Failure, death due to"
13,,,,,,
,aspergillosis,flavus,rhinocerebral,UTI,caspofungin,HD
